A Study on the Incidence and Prevalence of Cardiovascular Morbidity and Mortality in Patients Undergoing Maintenance Hemodialysis

Year : 2024 | Volume : 14 | Issue : 03 | Page : 56 66
    By

    Iqtisam Mushtaq Bhat,

  • Ibtisam Nazir Khan,

  • Pankaj Kaul,

  1. Student, Department of Allied & Health Sciences, Rayat Bahra University, Mohali, Punjab, India
  2. Assistant Professor, Department of Allied & Health Sciences, Rayat Bahra University, Mohali, Punjab, India
  3. Dean, Department of Allied & Health Sciences, Rayat Bahra University, Mohali, Punjab, India

Abstract

Cardiovascular Disease (CVD) is a major complication for patients with end-stage renal disease (ESRD) on Hemodialysis (HD), with the mortality rate from CVD being nearly 20 times higher than in the general population. As Chronic Kidney Disease (CKD) advances, patients accumulate both traditional and kidney-specific cardiovascular risk factors, such as hypertension, diabetes, fluid overload, electrolyte imbalances, and uremic toxins. These factors contribute significantly to the increased cardiovascular morbidity and mortality in this group. This study aimed to assess the incidence, prevalence, and variety of cardiovascular manifestations among CKD patients receiving maintenance hemodialysis (MHD) and to identify key risk factors for cardiovascular events in this population. A cross-sectional observational study was conducted with 50 CKD patients on MHD, with data collected through personal interviews using a structured questionnaire. The questionnaire included various parameters associated with cardiovascular outcomes in this group. Key assessments involved Electrocardiography (ECG), 2D Echocardiography, Stress Thallium Test, Stress Echocardiography, and Treadmill Test (TMT). Results indicated a high prevalence of hypertension and diabetes among the participants. Cardiovascular manifestations were common and diverse within the cohort, indicating a significant cardiovascular burden among patients undergoing MHD. CKD patients on MHD showed a high prevalence of CVD, with hypertension and diabetes as prominent risk factors. These findings underscore the importance of thorough cardiovascular evaluation and management for improving outcomes and reducing cardiovascular events in this high-risk population.

Keywords: Cardiovascular disease, chronic kidney disease, cardiovascular risk factors, cardiovascular morbidity, cardiovascular risk factors, diabetes

[This article belongs to Research & Reviews : A Journal of Life Sciences ]

aWQ6MTk1MTQ2fGZpbGVuYW1lOjk5OGY3NWZlLTgtcG5nLndlYnB8c2l6ZTp0aHVtYm5haWw=
How to cite this article:
Iqtisam Mushtaq Bhat, Ibtisam Nazir Khan, Pankaj Kaul. A Study on the Incidence and Prevalence of Cardiovascular Morbidity and Mortality in Patients Undergoing Maintenance Hemodialysis. Research & Reviews : A Journal of Life Sciences. 2024; 14(03):56-66.
How to cite this URL:
Iqtisam Mushtaq Bhat, Ibtisam Nazir Khan, Pankaj Kaul. A Study on the Incidence and Prevalence of Cardiovascular Morbidity and Mortality in Patients Undergoing Maintenance Hemodialysis. Research & Reviews : A Journal of Life Sciences. 2024; 14(03):56-66. Available from: https://journals.stmjournals.com/rrjols/article=2024/view=185573


Browse Figures

References

  1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998 Dec 1;9(12 Suppl):16–23.
  2. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J Am Soc Nephrol. 2001 Jul 1;12(7):1516–23.
  3. Foley RN, Parfrey PS. Cardiac disease in chronic uremia: clinical outcome and risk factors. Adv Renal Replace Ther. 1997 Jul 1;4(3):234–48.
  4. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 2004 Jun 1;65(6):2380–9.
  5. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. US Renal Data System 2011 annual data report. Am J Kidney Dis. 2012 Jan 1;59(1):A7.
  6. Bello AK, Johnson DW, Feehally J, Harris D, Jindal K, Lunney M, et al. Global Kidney Health Atlas GKHA: design and methods. Kidney Int Suppl. 2017 Oct 1;7(2):145–53.
  7. Bello AK, Levin A, Tonelli M, Okpechi IG, Feehally J, Harris D, et al. Assessment of Global Kidney Health Care Status. AGKHCS. Jama. 2017 May 9;317(18):1864–81.
  8. Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol. 2004 Jan 1;15(1_suppl):25–9.
  9. Le Feuvre C, Borenstein M, Beygui F, Helft G, Batisse JP, Metzger JP. Comparison of short-and long-term outcomes of coronary angioplasty in patients with and without diabetes mellitus and with and without hemodialysis. Am J Cardiol. 2003 Sep 15;92(6):721–5.
  10. Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int. 2002 Nov 1;62(5):1799–805.
  11. Metra M, Cannella G, La Canna G, Guaini T, Sandrini M, Gaggiotti M, et al.. Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. Am J Cardiol. 1991 Oct 15;68(10):1060–6.
  12. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. New Eng J Med. 1994 Mar 31;330(13):877–84.
  13. Buckalew Jr VM, Berg RL, Wang SR, Porush JG, Sally R, Schulman G. Modification of Diet in Renal Disease Study Group. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Am J Kidney Dis. 1996 Dec 1;28(6):811–21.
  14. Rocco MV, Flanigan MJ, Beaver S, Frederick P, Gentile DE, McClellan WM, et al. Report from the 1995 core indicators for peritoneal dialysis study group. Am J Kidney Dis. 1997 Aug 1;30(2):165–73.
  15. Fishbane S, Natke E, Maesaka JK. Role of volume overload in dialysis-refractory hypertension. Am J Kidney Dis. 1996 Aug 1;28(2):257–61.
  16. Venkatesan J, Henrich WL. Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. In Seminars in Nephrology. 1997 Jul 1;17(4)257–269.
  17. Silberberg JS, Rahal DP, Patton DR, Sniderman AD. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol. 1989 Jul 15;64(3):222–4.
  18. Macdougall IC, Coles GA, Williams JD, Davies ME, Hutton RD, Cochlin DL, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. The Lancet. 1990 Mar 3;335(8688):489–93.
Regular Issue Subscription Original Research
Volume 14
Issue 03
Received 08/10/2024
Accepted 18/11/2024
Published 26/11/2024
393

Login


My IP

PlumX Metrics